Top Markets
#1 Doge Strategy Doge Strategy +953,314.18%
#2 Noon Noon +12,208.80%
#3 Siren Siren +112.06%
#4 NEW X CEO IS BACK NEW X CEO IS BACK +109.20%
#5 Venom Venom +46.63%
#6 Gigachad Gigachad +28.15%
#7 Ontology Ontology +20.38%
#8 Scor Scor +18.84%
#9 Win Win +17.98%
#10 TRIA TRIA +17.79%
Coin of the day
Doge Strategy Doge Strategy
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Rang in Aktien #17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Aktienkurs
$0.0416118
Marktkapitalisierung
$12.78M
Veränderung (1 Tag)
1.72%
Veränderung (1 Jahr)
-22.01%
Land
AU
Handel Noxopharm Limited (NOX)

Kategorie

Healthcare
Gewinn für Noxopharm Limited (NOX)
Gewinn im Dec 2025 TTM: $-4.82M
Laut den aktuellen Finanzberichten von Noxopharm Limited betragen die aktuellen Gewinne des Unternehmens $-4.82M. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $-3.99M, eine Steigerung gegenüber dem Gewinn im Jahr 2023, der $-14.02M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Noxopharm Limited von 2016 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
2026 (TTM) $-4.82M 49.79%
2025 $-3.22M -19.45%
2024 $-3.99M -71.53%
2023 $-14.02M -15.43%
2022 $-16.58M 136.55%
2021 $-7.01M 23.32%
2020 $-5.68M -50.43%
2019 $-11.46M -19.51%
2018 $-14.24M 507.24%
2017 $-2.35M 334.19%
2016 $-540.21K 0.00%
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.46B -424,852.71%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B -96,506.98%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B -108,705.27%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -44,485.05%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -33,617.45%
AU